Centessa Pharmaceuticals plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q4 2020 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Centessa Pharmaceuticals plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q4 2020 to Q2 2024.
- Centessa Pharmaceuticals plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$43.1M, a 11.9% increase year-over-year.
- Centessa Pharmaceuticals plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2024 was -$158M, a 19.8% increase year-over-year.
- Centessa Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$176M, a 18.8% increase from 2022.
- Centessa Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$217M, a 43.1% increase from 2021.
- Centessa Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$381M, a 3473% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)